Advance the clinical development of emodepside as an anti-parasitic macrofilaricidal treatment
current phase of drug development
updated 1 Mar 2022
Emodepside, an antihelminthic veterinary drug for cats and dogs, was originated by the Japanese pharmaceutical company Astellas and then developed and commercialized by Bayer Animal Health. DNDi, in collaboration with Bayer AG, is evaluating emodepside as a potential anti-parasitic macrofilaricidal treatment for onchocerciasis in humans.
Under a joint development agreement, Bayer AG provides the active ingredient emodepside to DNDi, who is responsible for its clinical development; Bayer AG is responsible for pre-clinical and pharmaceutical development, as well as registration, manufacturing, and distribution of the drug.
First-in-human Phase I studies for emodepside in healthy volunteers have successfully been completed, including both a single ascending dose study in 2017 and a multiple ascending dose study in 2018. Emodepside is orally bioavailable, and a tablet that could be commercialized has been developed.
Next, DNDi will launch a Phase II proof-of-concept clinical trial to investigate the safety and efficacy of emodepside for people living with onchocerciasis.
News and publications
- Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside. PLOS Neglected Tropical Diseases, March 2022
- Development of emodepside as a possible adulticidal treatment for human onchocerciasis—The fruit of a successful industrial–academic collaboration. PLOS Pathogens, July 2021
- Safety, tolerability, and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects. British Journal of Clinical Pharmacology, March 2021
- 9 December 2014 – Bayer and DNDi sign first agreement to develop an innovative oral treatment for human river blindness
Get our latest news, personal stories, research articles, and job opportunities.